Two-Tiered Newborn Screening with Post-Analytical Tools for Pompe Disease and Mucopolysaccharidosis Type I Results in Performance Improvement and Future Direction

Two-Tiered Newborn Screening with Post-Analytical Tools for Pompe Disease and Mucopolysaccharidosis Type I Results in Performance Improvement and Future Direction

We conducted a pilot newborn screening (NBS) study for Pompe disease (PD) and mucopolysaccharidosis type I (MPS I) in the multiethnic population of Georgia. We screened 59,332 infants using a two-tier strategy of flow injection tandem mass spectrometry (FIA-MSMS) enzyme assays. The first tier of tes...

Full description

Bibliographic Details
Main Authors:	Patricia L. Hall, Rossana Sanchez, Arthur F. Hagar, S. Caleb Jerris, Angela Wittenauer, William R. Wilcox
Format:	Article
Language:	English
Published:	MDPI AG 2020-01-01
Series:	International Journal of Neonatal Screening
Subjects:	newborn screening post-analytical tools pompe disease mucopolysaccharidosis type i pseudodeficiency
Online Access:	https://www.mdpi.com/2409-515X/6/1/2

Similar Items

Newborn Screening for Mucopolysaccharidosis Type II in Illinois: An Update
by: Barbara K. Burton, et al.
Published: (2020-09-01)

Lessons Learned from Pompe Disease Newborn Screening and Follow-up
by: Tracy L. Klug, et al.
Published: (2020-02-01)

Newborn Screening for Pompe Disease
by: Takaaki Sawada, et al.
Published: (2020-04-01)

A Biochemical Platform to Define the Relative Specific Activity of <i>IDUA</i> Variants Identified by Newborn Screening
by: Seok-Ho Yu, et al.
Published: (2020-11-01)

Post-Analytical Tools for the Triage of Newborn Screening Results in Follow-up Can Reduce Confirmatory Testing and Guide Performance Improvement
by: Patricia L. Hall, et al.
Published: (2020-03-01)

Molecular study of Pompe disease in Egyptian infants
by: Mona Essawi, et al.
Published: (2021-11-01)

Harmonization of Newborn Screening Results for Pompe Disease and Mucopolysaccharidosis Type I
by: M. Christine Dorley, et al.
Published: (2023-02-01)

The First Year Experience of Newborn Screening for Pompe Disease in California
by: Hao Tang, et al.
Published: (2020-02-01)

Newborn Screening for Pompe Disease: Pennsylvania Experience
by: Can Ficicioglu, et al.
Published: (2020-11-01)

The Impact of Post-Analytical Tools on New York Screening for Krabbe Disease and Pompe Disease
by: Monica M. Martin, et al.
Published: (2020-08-01)

Muscle ultrasound in patients with late-onset Pompe disease identified by newborn screening
by: David G. Jackson, et al.
Published: (2023-09-01)

Establishing Pompe Disease Newborn Screening: The Role of Industry
by: Joan M. Keutzer
Published: (2020-07-01)

Performance of the Four-Plex Tandem Mass Spectrometry Lysosomal Storage Disease Newborn Screening Test: The Necessity of Adding a 2nd Tier Test for Pompe Disease
by: Shu-Chuan Chiang, et al.
Published: (2018-12-01)

At-Risk Testing for Pompe Disease Using Dried Blood Spots: Lessons Learned for Newborn Screening
by: Zoltan Lukacs, et al.
Published: (2020-12-01)

Validation and Implementation of a Highly Sensitive and Efficient Newborn Screening Assay for Mucopolysaccharidosis Type II
by: Heather Bilyeu, et al.
Published: (2020-10-01)

Is Newborn Screening the Ultimate Strategy to Reduce Diagnostic Delays in Pompe Disease? The Parent and Patient Perspective
by: Raymond Saich, et al.
Published: (2020-01-01)

Newborn Screening for Mucopolysaccharidosis I: Moving Forward Learning from Experience
by: Lorne A. Clarke, et al.
Published: (2020-11-01)

Expanding Newborn Screening for Pompe Disease in the United States: The NewSTEPs New Disorders Implementation Project, a Resource for New Disorder Implementation
by: Kshea Hale, et al.
Published: (2020-06-01)

Investigation of newborns with abnormal results in a newborn screening program for four lysosomal storage diseases in Brazil
by: Heydy Bravo, et al.
Published: (2017-09-01)

Mutational spectrum and genotype–phenotype correlation in Mexican patients with infantile‐onset and late‐onset Pompe disease
by: Valentina Martinez‐Montoya, et al.
Published: (2024-07-01)

Newborn Screening for X-Linked Adrenoleukodystrophy in Georgia: Experiences from a Pilot Study Screening of 51,081 Newborns
by: Patricia L. Hall, et al.
Published: (2020-10-01)

A Qualitative Study: Mothers’ Experiences of Their Child’s Late-Onset Pompe Disease Diagnosis Following Newborn Screening
by: Kaylee Crossen, et al.
Published: (2022-07-01)

Enzymatic testing for mucopolysaccharidosis type I in Kuwaiti newborns: a preliminary study toward newborn screening
by: Hind Alsharhan, et al.
Published: (2024-07-01)

Safety outcomes and patients’ preferences for home-based intravenous enzyme replacement therapy (ERT) in pompe disease and mucopolysaccharidosis type I (MPS I) disorder: COVID-19 and beyond
by: Antonio Toscano, et al.
Published: (2023-10-01)

A Comparative Effectiveness Study of Newborn Screening Methods for Four Lysosomal Storage Disorders
by: Karen A. Sanders, et al.
Published: (2020-05-01)

Light and Shadows in Newborn Screening for Lysosomal Storage Disorders: Eight Years of Experience in Northeast Italy
by: Vincenza Gragnaniello, et al.
Published: (2023-12-01)

Extremely low arylsulfatase A enzyme activity does not necessarily cause symptoms: A long‐term follow‐up and review of the literature
by: Lucia Laugwitz, et al.
Published: (2022-07-01)

Evaluation of Multiple Methods for Quantification of Glycosaminoglycan Biomarkers in Newborn Dried Blood Spots from Patients with Severe and Attenuated Mucopolysaccharidosis-I
by: Zackary M. Herbst, et al.
Published: (2020-08-01)

Characteristics of Pompe disease in China: a report from the Pompe registry
by: Yuying Zhao, et al.
Published: (2019-04-01)

Evaluation of Two Methods for Quantification of Glycosaminoglycan Biomarkers in Newborn Dried Blood Spots from Patients with Severe and Attenuated Mucopolysaccharidosis Type II
by: Zackary M. Herbst, et al.
Published: (2022-01-01)

The Clinical Management of Pompe Disease: A Pediatric Perspective
by: Jorge Sales Marques
Published: (2022-09-01)

Newborn screening for Pompe disease in Italy: Long-term results and future challenges
by: Vincenza Gragnaniello, et al.
Published: (2022-12-01)

Implementing Statewide Newborn Screening for New Disorders: U.S. Program Experiences
by: Yvonne Kellar-Guenther, et al.
Published: (2020-04-01)

Frequency of iduronate-2-sulfatase gene variants detected in newborn screening for mucopolysaccharidosis type II in Japan
by: Yusuke Hattori, et al.
Published: (2023-12-01)

Earlier and higher dosing of alglucosidase alfa improve outcomes in patients with infantile-onset Pompe disease: Evidence from real-world experiences
by: Yin-Hsiu Chien, et al.
Published: (2020-06-01)

A Newborn Screening, Presymptomatically Identified Infant With Late-Onset Pompe Disease: Case Report, Parental Experience, and Recommendations
by: Raymond Y. Wang
Published: (2020-03-01)

Development of a newborn screening tool for mucopolysaccharidosis type I based on bivariate normal limits: Using glycosaminoglycan and alpha‐L‐iduronidase determinations on dried blood spots to predict symptoms
by: Thomas J. Langan, et al.
Published: (2020-03-01)

Newborn screening in mucopolysaccharidoses
by: Maria Alice Donati, et al.
Published: (2018-11-01)

Development of a clinically validated in vitro functional assay to assess pathogenicity of novel GAA variants in patients with Pompe disease identified via newborn screening
by: Shelly Goomber, et al.
Published: (2022-09-01)

Optimizing clinical outcomes: The journey of twins with CRIM-negative infantile-onset Pompe disease on high-dose enzyme replacement therapy and immunomodulation
by: Angie H. Fares, et al.
Published: (2024-12-01)